Apyx Medical upgraded to Buy from Neutral at BTIG
BTIG analyst Sam Eiber upgraded Apyx Medical (APYX) to Buy from Neutral with a $6 price target The firm cites positive early momentum with the Ayon launch, growing demand for skin tightening among consumers taking GLP-1s, and Apyx Medical’s expansion opportunities outside the U.S. for the upgrade. Accelerating growth and cost controls offer greater visibility into the company’s path to sustainable profitability, which had been a previous core concern, the analyst tells investors in a research note.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MERGE Madrid 2026: Info and Promo Code
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 01:18 PM
Lundin Gold hits record 1035g in Ecuador
NASDAQ TRADE HALT <QH.O> VOLATILITY TRADING PAUSE AT 01:12 PM
